Abstract: The present invention provides a production method of ?-fluoroacrylate ester, a composition containing a highly-pure fluorocyclopropane derivative and a composition containing highly-pure ?-fluoroacrylate ester.

Abstract: The present invention relates to a novel prostaglandin derivative having an alkynyl group on ?-chain, particularly, a novel prostaglandin derivative having a double bond at the 2-position and an alkynyl group on the ?-chain and a medicament containing the compound as an active ingredient. According to the present invention, a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof; wherein each symbol is as defined in the present specification, or a cyclodextrin clathrate compound thereof, and a medicament containing the compound as an active ingredient, particularly, a medicament for the prophylaxis or treatment of a blood flow disorder associated with spinal canal stenosis or chronic arterial occlusion, can be provided.

Abstract: The present invention provides a production method of ?-fluoroacrylate ester, a composition containing a highly-pure fluorocyclopropane derivative and a composition containing highly-pure ?-fluoroacrylate ester.

Abstract: The present invention relates to a novel prostaglandin derivative having an alkynyl group on ?-chain, particularly, a novel prostaglandin derivative having a double bond at the 2-position and an alkynyl group on the ?-chain and a medicament containing the compound as an active ingredient. According to the present invention, a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof; wherein each symbol is as defined in the present specification, or a cyclodextrin clathrate compound thereof, and a medicament containing the compound as an active ingredient, particularly, a medicament for the prophylaxis or treatment of a blood flow disorder associated with spinal canal stenosis or chronic arterial occlusion, can be provided.

Abstract: To provide a novel method for producing a halogenated acrylic acid derivative. A compound represented by the formula (1): (wherein each of R1 and R2 which are independent of each other, is a hydrogen atom or a monovalent group essentially containing a carbon atom, or R1 and R2 together form a ring, R3 is a monovalent group capable of being desorbed by R3OH removal reaction, and each of R4 and R5 which are independent of each other, is a hydrogen atom or a monovalent group essentially containing a carbon atom) and having a boiling point of at most 500° C.

Abstract: To provide a novel method for producing a halogenated acrylic acid derivative. A compound represented by the formula (1): (wherein each of R1 and R2 which are independent of each other, is a hydrogen atom or a monovalent group essentially containing a carbon atom, or R1 and R2 together form a ring, R3 is a monovalent group capable of being desorbed by R3OH removal reaction, and each of R4 and R5 which are independent of each other, is a hydrogen atom or a monovalent group essentially containing a carbon atom) and having a boiling point of at most 500° C.

Abstract: To provide a composition for hair growth (hair growth agent) which has high hair growing effects and can be used for prevention or treatment of alopecia. The composition for hair growth comprises as an active ingredient at least one member selected from the group consisting of a compound represented by the formula (1) and a salt thereof. In the formula, R is a carboxy group or an alkoxycarbonyl group.

Abstract: Quinolin-2-yl benzoic acid compounds which are useful as intermediates of quinoline compounds having angiotensin II antagonist activity prepared by decarboxylating 2-(carboxyphenyl)-4-quinolinecarboxylic acid compounds in which a carboxyl group bonded to a phenyl group may be esterified, while a carboxyl group bonded to a quinoline ring is not esterified, and both rings may have one or more substituents inert to the decarboxylation reaction.

Abstract: A quinoline compound represented by the formula (1) or a salt thereof: ##STR1## wherein the definition of each substituents are described in the specification, which have angiotensin II antagonism and hypotensive action and are useful as an agent for the prevention and treatment of cardiovascular system diseases such as hypertension, heart failure and the like.

Abstract: A quinoline compound represented by the formula (1) or a salt thereof: ##STR1## wherein the definition of each substituents are described in the specification, which have angiotensin II antagonism and hypotensive action and are useful as an agent for the prevention and treatment of cardiovascular system diseases such as hypertension, heart failure and the like.

Abstract: A novel prostaglandin I.sub.2 derivative selected from a prostaglandin I.sub.2 having a halogen atom on the carbon atom corresponding to the 7-position of natural prostaglandin I.sub.2 and having a cycloalkylene group in the .alpha.-chain, and its esters and salts.

Abstract: An isoindazole compound of the formula (1) or a salt thereof; a method for the production thereof; and pharmaceutical use of the compound and a salt thereof, particularly as an angiotensin II antagonist and as an agent for the prophylaxis and treatment of circulatory diseases (particularly hypertension and heart failure); ##STR1## wherein Q is a heterocyclic derivative of the formula (2) or (3) ##STR2## wherein other symbols of the above formulas are as defined in the Specification. The compound and its salt show superior angiotensin II antagonism and are low toxic. Accordingly, they are useful as angiotensin II antagonists for the treatment or prophylaxis of angiotensin II-mediated diseases such as circulatory diseases of hypertension (e.g. essential hypertension, renal hypertension) and heart failure.

Abstract: An emulsion of lipid containing a prostaglandin analogue of the formula (1): ##STR1## wherein R.sup.1 is an alkanoyl group, R.sup.2 is a hydrogen atom or an alkyl group, each of R.sup.3 and R.sup.4 is a hydrogen atom or a protective group for an alcohol, R.sup.5 is an alkyl group which may have a substitutent, and is a single bond or a double bond.

Abstract: An emulsion of lipid containing a prostaglandin analogue of the formula (1): ##STR1## wherein R.sup.1 is an alkanoyl group, R.sup.2 is a hydrogen atom or an alkyl group, each of R.sup.3 and R.sup.4 is a hydrogen atom or a protective group for an alcohol, R.sup.5 is an alkyl group which may have a substituent, and is a single bond or a double bond.

Abstract: A 6-fluoroprostaglandin having the formula: ##STR1## wherein A is a carbonyl group or a hydroxymethylene group, R.sup.1 is a substituted or unsubstituted C.sub.1 -C.sub.10 alkyl group or a substituted or unsubstituted 5- or 6-membered cycloalkyl group, R.sup.2 is a hydrogen atom or a C.sub.1 -C.sub.10 alkyl group, each of R.sup.3 and R.sup.4 which may be the same or different is a hydrogen atom or a protecting group, R.sup.5 is a hydrogen atom or a hydroxyl group, and is a single bond or a double bond, and its salt when R.sup.2 is a hydrogen atom.